Alnylam Grants New InterfeRx(TM) Intellectual Property License to ... PR-Inside.com (Pressemitteilung), Austria - RNAi therapeutics target the cause of diseases by potently silencing specific messenger RNAs (mRNAs), thereby preventing disease-causing proteins from being ... |
Comments